Portal de Periódicos da CAPES

Interferon‐α for Viral Hepatitis

1996; Lippincott Williams & Wilkins; Volume: 23; Issue: 2 Linguagem: Inglês

10.1002/j.1536-4801.1996.tb00311.x

1536-4801

Maureen M. Jonas,

Liver Disease Diagnosis and Treatment

Journal of Pediatric Gastroenterology and NutritionVolume 23, Issue 2 p. 93-106 Invited Review Interferon-α for Viral Hepatitis Maureen M. Jonas, Corresponding Author Maureen M. Jonas n/[email protected] Combined Program in Gastroenterology, Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, U.S.A.Address correspondence and reprint requests to Dr. Maureen M. Jonas, Department of Pediatrics, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, U.S.A.Search for more papers by this author Maureen M. Jonas, Corresponding Author Maureen M. Jonas n/[email protected] Combined Program in Gastroenterology, Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, U.S.A.Address correspondence and reprint requests to Dr. Maureen M. Jonas, Department of Pediatrics, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, U.S.A.Search for more papers by this author First published: 01 August 1996 https://doi.org/10.1002/j.1536-4801.1996.tb00311.xCitations: 5Read the full textAbout ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Issacs A, Lindenmann J. Virus interferons. I. The interferon. Proc R Soc Lond 1957; 147: 258–67. 10.1098/rspb.1957.0048 PubMedWeb of Science®Google Scholar 2Stewart, WE. The inferferon system. 2nd ed. New York: Springer-Verlag, 1979. 10.1007/978-3-7091-3432-0 Google Scholar 3Blanar MA, Boettger EC, Flavell RA. Transcriptional activation of HLA-DR alpha by interferon gamma requires a transacting protein. Proc Natal Acad Acad Sci USA 1988; 85: 4672–6. 10.1073/pnas.85.13.4672 CASPubMedWeb of Science®Google Scholar 4DeMaeyer E, DeMaeyer-Guignard J. Enhanced phagocytic activity of macrophages against Candida albicans. Interferon effects on cellular and humoral immunity. In: S Baron, F Dianzani, GJ Stanton, WR Fleischmann, eds. The interferon system: a current review to 1987. Austin, TX: Univ. of Texas Medical Branch Series, 1987: 327–35. Google Scholar 5Taniguchi T. Regulation of cytokine gene expression. Annu Rev Immunol 1988; 6: 439–4. 10.1146/annurev.iy.06.040188.002255 CASPubMedWeb of Science®Google Scholar 6Peters M, Ambrus JL, Zhelenznyak A, et al. Effect of alpha interferon on immunoglobulin synthesis by human B cells. J Immunol 1986; 137: 3153–7. 10.4049/jimmunol.137.10.3153 CASPubMedWeb of Science®Google Scholar 7Snapper CM, Paul WE. Interferon gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944–7. 10.1126/science.3107127 CASPubMedWeb of Science®Google Scholar 8Trotta PP, Narula SK. Interferon genes. In: S Baron, F Dianzani, GJ Stanton, WR Fleischmann, eds. The Interferon system: a current review to 1987. Austin, TX Univ. of Texas Press, 1987: 137–47. Google Scholar 9Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer F. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immunol 1993; 150: 707–16. 10.4049/jimmunol.150.3.707 CASPubMedWeb of Science®Google Scholar 10Gray PW, Leung DW, Pennica D, et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 1982; 295: 503–8. 10.1038/295503a0 CASPubMedWeb of Science®Google Scholar 11Fitzgerald-Bocarsly P. Human natural interferon-alpha producing cells. Pharmacol Therapeut 1993; 60: 39–62. 10.1016/0163-7258(93)90021-5 CASPubMedWeb of Science®Google Scholar 12Zoon KC, Arnheiter H. Studies of the antigens receptors. Pharmacol Therapeut 1984; 24: 259–78. 10.1016/0163-7258(84)90037-8 CASPubMedWeb of Science®Google Scholar 13Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415–21. 10.1126/science.8197455 CASPubMedWeb of Science®Google Scholar 14Peters M. Mechanism of action of interferons. Semin Liv Dis 1989; 9: 235–9. 10.1055/s-2008-1040516 CASPubMedWeb of Science®Google Scholar 15Baglioni C, Maroney TA, West DK. 2′5′-oligo(A)polymerase activity and inhibition of viral RNA synthesis in interferon treated HeLa cells. Biochemistry 1979; 18: 1765–70. 10.1021/bi00576a020 CASPubMedWeb of Science®Google Scholar 16Samuel CE. The interferon-induced protein P1/eIF-2 alpha kinase. In: S Baron, S Dianzani, GJ Stanton, WR Fleischmann, eds. The interferon system: a current review to 1987. Austin, TX: Univ. of Texas Press, 1987: 373–81. Google Scholar 17Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol 1990; 82: 57–62. 10.1111/j.1365-2249.1990.tb05403.x CASPubMedWeb of Science®Google Scholar 18Antonelli G, Currenti M, Turrizziani O, et al. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882 10.1093/infdis/163.4.882 CASPubMedWeb of Science®Google Scholar 19Porres JC, Carreno V, Ruiz M, et al. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 1989; 8: 351–7. 10.1016/0168-8278(89)90034-2 CASPubMedWeb of Science®Google Scholar 20Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266–70. 10.1002/hep.1840120603 CASPubMedWeb of Science®Google Scholar 21Bonetti P, Diodati G, Drago C, et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. J Hepatol 1994; 20: 416–20. 10.1016/S0168-8278(94)80018-9 CASPubMedWeb of Science®Google Scholar 22Douglas DD, Rakela J, Lin HJ, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993; 38: 601–7. 10.1007/BF01316787 CASPubMedWeb of Science®Google Scholar 23Thomas HC, Water JM, Waters J, Main J. Virus-host interactions in chronic hepatitis B infection. Semin Liv Dis 1988; 8: 342–9. 10.1055/s-2008-1040555 CASPubMedWeb of Science®Google Scholar 24Desmet VJ. Immunopathology of chronic viral hepatitis. Hepatogastroenterology 1991; 38: 14–21. CASPubMedWeb of Science®Google Scholar 25Tolentino P, Dianzani F, Zucca M, Giacchino R. Decreased interferon response by lymphocytes in children with chronic hepatitis. J Infect Dis 1975; 132: 439–63. 10.1093/infdis/132.4.459 Web of Science®Google Scholar 26Ikeda T, Lever AML, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986; 6: 962–5. 10.1002/hep.1840060525 CASPubMedWeb of Science®Google Scholar 27Greenberg HB, Pollard RB, Lutwick LI, et al. Effects of human leucocyte interferon and hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517–22. 10.1056/NEJM197609022951001 CASPubMedWeb of Science®Google Scholar 28Perillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301. 10.1056/NEJM199008023230503 PubMedWeb of Science®Google Scholar 29Feinman SV, Berris B, Sooknanan R, et al. Effects of interferon-alfa therapy on serum and liver HBV DNA in patients with chronic hepatitis B. Dig Dis Sci 1992; 37: 1477–82. 10.1007/BF01296489 CASPubMedWeb of Science®Google Scholar 30Fong T-L, DiBisceglie AM, Feinstone SM, et al. Persistent hepatic HBV DNA after clearance of HBsAg from serum of patient with chronic hepatitis B [Abstract]. Hepatology 1991; 14: 130A Web of Science®Google Scholar 31Marcellin P, Martinot-Peignoux M, Lariot MA, et al. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. Ann Intern Med 1990; 112: 227–8. 10.7326/0003-4819-112-3-227 CASPubMedWeb of Science®Google Scholar 32Khuns M, McNamara A, Mason A, et al. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103: 1649–56. 10.1016/0016-5085(92)91191-6 PubMedWeb of Science®Google Scholar 33Hoofnagle JH, Peters M, Mullen KD, et al. Randmoized, controlled trial of recombinant human alfa-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318–25. 10.1016/0016-5085(88)90367-8 CASPubMedWeb of Science®Google Scholar 34Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. Ann Intern Med 1993; 119: 312–23. 10.7326/0003-4819-119-4-199308150-00011 CASPubMedWeb of Science®Google Scholar 35Lok ASF, Lai CL, Su PC, et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liv Dis 1989; 9: 249–53. 10.1055/s-2008-1040518 CASPubMedWeb of Science®Google Scholar 36Perillo RP. Antiviral agents in the treatment of chronic viral hepatitis. In: JL Boyer, RK Ockner, eds. Progress in liver disease; vol X. Philadelphia: WB Saunders, 1992: 283–309. Google Scholar 37Perrillo RP. Interferon in the management of chronic hepatitis B. Dig Dis Sci 1993; 38: 577–93. 10.1007/BF01316785 CASPubMedWeb of Science®Google Scholar 38Brook MG, Karayiannis P. Thomas HC. Patients with chronic hepatitis V virus infection will respond to alpha interferon therapy: a statistical analysis of predictive factors. Hepatology 1989; 10: 761–3. 10.1002/hep.1840100502 CASPubMedWeb of Science®Google Scholar 39Naoumov NV, Thomas MG, Mason AL, et al. Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment. Gastroenterology 1995; 108: 505–14. 10.1016/0016-5085(95)90080-2 CASPubMedWeb of Science®Google Scholar 40Nevens F, Goubau P, Van Eyken P, et al. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993; 13: 15–9. 10.1111/j.1600-0676.1993.tb00599.x CASPubMedWeb of Science®Google Scholar 41Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629–34. 10.7326/0003-4819-114-8-629 CASPubMedWeb of Science®Google Scholar 42Carreno V, Castillo I, Molina J, et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102–6. 10.1016/0168-8278(92)90019-L CASPubMedWeb of Science®Google Scholar 43 Centers for Disease Control. Hepatitis surveillance report no. 54. Atlanta, GA: Centers for Disease Control, 1992; 11. Google Scholar 44Hostetter MK, Iverson S, Dole K, Johnson D. Unsuspected infectious diseases and other medical diagnoses in the evaluation of internationally adopted children. Pediatrics 1989; 83: 559–64. 10.1542/peds.83.4.559 CASPubMedWeb of Science®Google Scholar 45McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599–603. 10.1093/infdis/151.4.599 CASPubMedWeb of Science®Google Scholar 46Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha2-interferon in Chinese HBsAg-carrier children. Lancet 1987; 2: 877–80. 10.1016/S0140-6736(87)91371-7 CASPubMedWeb of Science®Google Scholar 47Tanaka T, Miyamoto H, Hino O, et al. Primary hepatocellular carcinoma with hepatitis B virus-DNA-integration in a 4-year-old boy. Hum Pathol 1986; 17: 202 10.1016/S0046-8177(86)80296-9 CASPubMedWeb of Science®Google Scholar 48Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer 1990; 65: 174–6. 10.1002/1097-0142(19900101)65:1 3.0.CO;2-K CASPubMedWeb of Science®Google Scholar 49Giacchino R, Navone C, Facco F, et al. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci 1991; 36: 1143–6. 10.1007/BF01297462 CASPubMedWeb of Science®Google Scholar 50Pontisso P, Basso G, Perilongo G, et al. Does hepatitis B virus play a role in primary liver cancer in children of Western countries? Cancer Detect Prev 1991; 15: 363–8. CASPubMedWeb of Science®Google Scholar 51Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha-2a-interferon: a controlled, randomized study. Am J Gastroenterol 1991; 86: 327–30. CASPubMedWeb of Science®Google Scholar 52Ruiz-Moreno M, Jimenez J, Porres JC, et al. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990; 45: 26–33. 10.1159/000200221 CASPubMedWeb of Science®Google Scholar 53Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13: 1035–9. 10.1002/hep.1840130605 CASPubMedWeb of Science®Google Scholar 54Bruguera M, Amat L, Garcia O, et al. Treatment of chronic hepatitis B in children with recombinant alfa interferon. Different response according to age at infection. J Clin Gastroenterol 1993; 17: 296–9. 10.1097/00004836-199312000-00006 CASPubMedWeb of Science®Google Scholar 55Utili R, Sagnelli E, Baeta GB, et al. Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. J Hepatol 1994; 20: 163–7. 10.1016/S0168-8278(05)80053-4 CASPubMedWeb of Science®Google Scholar 56Lok AS. Alpha-interferon therapy for chronic hepatitis B virus infection in children and Oriental patients. J Gastroenterol Hepatol 1991;(suppl 1): 15–7. Google Scholar 57Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78: 155–63. CASPubMedWeb of Science®Google Scholar 58Mosnier J-F, Degott C, Marcellin P, et al. The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology 1993; 17: 366–71. 10.1002/hep.1840170304 CASPubMedWeb of Science®Google Scholar 59James-Koziel M, Dudley D, Wong JT, et al. Intraphepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339–44. 10.4049/jimmunol.149.10.3339 PubMedWeb of Science®Google Scholar 60Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841–8. 10.1002/hep.1840190407 CASPubMedWeb of Science®Google Scholar 61Mishiro S, Hoshi Y, Takeda K, et al. Non-A, non-B specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet 1990; 336: 1400–3. 10.1016/0140-6736(90)93101-T CASPubMedWeb of Science®Google Scholar 62Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315: 1575–8. 10.1056/NEJM198612183152503 CASPubMedWeb of Science®Google Scholar 63Shindo M, DiBisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 11: 700–4. 10.7326/0003-4819-115-9-700 Google Scholar 64DiBisceglie AM, Hoofnagle JH, Krawczynski K. Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology 1993; 105: 858–62. 10.1016/0016-5085(93)90905-R CASPubMedWeb of Science®Google Scholar 65Lau JYN, Mizokami M, Chno T, et al. Discrepancy between biochemical and virologic responses to interferon therapy in patients with chronic hepatitis C. Lancet 1993; 342: 1208–9. 10.1016/0140-6736(93)92187-X CASPubMedWeb of Science®Google Scholar 66Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–6. 10.1056/NEJM198911303212203 CASPubMedWeb of Science®Google Scholar 67DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10. 10.1056/NEJM198911303212204 CASPubMedWeb of Science®Google Scholar 68Tine F, Magrin S, Craxi A, et al. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192–9. 10.1016/0168-8278(91)90814-R CASPubMedWeb of Science®Google Scholar 69Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks. Hepatology 1994; 19: 280–5. 10.1002/hep.1840190204 CASPubMedWeb of Science®Google Scholar 70Liaw F, Sheen I-S, Lin S-M, et al. Effects of prednisone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993; 13: 46–60. 10.1111/j.1600-0676.1993.tb00604.x CASPubMedWeb of Science®Google Scholar 71Yamada G, Takahashi M, Tsuji T, et al. Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C treated with interferon alfa. Dig Dis Sci 1992; 37: 1926–7. 10.1007/BF01308091 CASPubMedWeb of Science®Google Scholar 72Kobayashi Y, Natanabe S, Konishi M, et al. Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non-A, non-B hepatitis treated with interferon. J Hepatol 1992; 16: 138–44. 10.1016/S0168-8278(05)80106-0 CASPubMedWeb of Science®Google Scholar 73Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299–305. 10.1002/jmv.1890420318 CASPubMedWeb of Science®Google Scholar 74Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151–6. CASPubMedWeb of Science®Google Scholar 75Yun ZB, Reichard O, Chen M, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C—importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 1994; 26: 263–70. 10.3109/00365549409011794 CASPubMedWeb of Science®Google Scholar 76Aiyama T, Yoshioka K, Hirofuji H, et al. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 2244–9. 10.1007/BF02090379 CASPubMedWeb of Science®Google Scholar 77Kanai K, Kako M, Okamato H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543 10.1016/0140-6736(92)91311-U CASPubMedWeb of Science®Google Scholar 78Matsumoto A, Tanaka E, Suzuki T, et al. Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1273–80. 10.1007/BF02093793 CASPubMedWeb of Science®Google Scholar 79Kleter GEM, Brouwer JT, Heijtink RA, et al. Detection of hepatitis C virus RNA in patients with chronic hepatitis C infection during and after therapy with alpha interferon. Antimicrob Agents Chemother 1993; 37: 595–7. 10.1128/AAC.37.3.595 CASPubMedWeb of Science®Google Scholar 80Dimopoulou M, Fafontis K, Basiliou K, et al. Interferon alfa 2b for decompensated liver disease caused by either chronic hepatitis B or C: preliminary results of a pilot study [Abstract]. Gut 1993; 34 (suppl): 104–5. 10.1136/gut.34.2_Suppl.S104 Google Scholar 81Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914–5. 10.1016/0140-6736(91)91774-O CASPubMedWeb of Science®Google Scholar 82Viladomiu L, Genesca J, Esteban JI, et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 1992; 15: 767–9. 10.1002/hep.1840150504 CASPubMedWeb of Science®Google Scholar 83Colombo M, Lampertico P, Rumi M. Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion. Gut 1993;(suppl): s141. Google Scholar 84Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alfa 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19: 19–22. 10.1002/hep.1840190105 CASPubMedWeb of Science®Google Scholar 85Resti M, Azzari C, Rossi ME, et al. Prevalence of hepatitis C virus antibody in beta-thalassemic polytransfused children in a long-term follow-up. Vox Sang 1991; 60: 246–7. 10.1111/j.1423-0410.1991.tb00916.x CASPubMedWeb of Science®Google Scholar 86Lai ME, DeVirgilis S, Argiolu F, et al. Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. J Pediatr Gastroenterol Nutr 1993; 16: 458–64. 10.1002/j.1536-4801.1993.tb10896.x CASPubMedWeb of Science®Google Scholar 87Troisi CL, Hollinger B, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412–8. 10.1182/blood.V81.2.412.412 CASPubMedWeb of Science®Google Scholar 88Greco M, Cristiano K, Leozappa G, et al. Hepatitis C infection in children and adolescents on haemodialysis and after renal transplant. Pediatr Nephrol 1993; 7: 424–7. 10.1007/BF00857557 CASPubMedWeb of Science®Google Scholar 89Jonas MM, Zilleruelo GE, LaRue SI, et al. Hepatitis C in a pediatric dialysis population. Pediatrics 1992; 89: 707–9. 10.1542/peds.89.4.707 CASPubMedWeb of Science®Google Scholar 90Locasciulli A, Gornati G, Tagger A, et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long-term remission. Blood 1991; 78: 1619–22. 10.1182/blood.V78.6.1619.1619 CASPubMedWeb of Science®Google Scholar 91Rossetti F, Cesaro S, Pizzocchero P, et al. Chronic hepatitis B surface antigen-negative hepatitis after treatment of malignancy. J Pediatr 1992; 121: 39–43. 10.1016/S0022-3476(05)82538-7 CASPubMedWeb of Science®Google Scholar 92Tanaka E, Kiyosawa K, Soeyama T, et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am J Trop Med Hyg 1992; 46: 460–4. 10.4269/ajtmh.1992.46.460 CASPubMedWeb of Science®Google Scholar 93Ngatchu T, Stroffolini T, Rapicetta M, et al. Seroprevalence of anti-HCV in an urban child population: a pilot survey in a developing area, Cameroon. J Trop Med Hyg 1992; 95: 57–61. CASPubMedWeb of Science®Google Scholar 94Riestra-Menendez S, Rodriguez-Garcia M, Sanchez-SanRoman F, et al. Intrafamilial spread of hepatitis C virus. Infection 1991; 19: 431–3. 10.1007/BF01726456 CASPubMedWeb of Science®Google Scholar 95Pramoolsinsap C, Kurathong S, Lerdverasirikul P. Prevalence of anti-HCV antibody in family members of anti-HCV-positive patients with acute and chronic liver disease. Southeast Asian J Trop Med Pub Hlth 1992; 23: 12–6. CASPubMedGoogle Scholar 96Al Nasser MN. Intrafamilial transmission of hepatitis C virus (HCV): a major mode of spread in the Saudi Arabia population. Ann Trop Pediatr 1992; 12: 211–5. 10.1080/02724936.1992.11747570 CASPubMedWeb of Science®Google Scholar 97Hsu S-C, Chang M-H, Chen D-S, et al. Non-A, non-B hepatitis in children: a clinical, histologic, and serologic study. J Med Virol 1991; 35: 1–6. 10.1002/jmv.1890350102 CASPubMedWeb of Science®Google Scholar 98Bortolotti F, Vajro P, Cadrobbi P, et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992; 15: 73–6. 10.1016/0168-8278(92)90014-G CASPubMedWeb of Science®Google Scholar 99Nagata I, Shiraki K, Tanimoto K, et al. Mother-to-infant transmission of hepatitis C virus. J Pediatr 1992; 120: 432–4. 10.1016/S0022-3476(05)80914-X CASPubMedWeb of Science®Google Scholar 100Kuroki T, Nishiguchi S, Fukuda K, et al. Vertical transmission of hepatitis C virus (HCV) detected by HCV-RNA analysis. Gut 1993; 34: s52–3. 10.1136/gut.34.2_Suppl.S52 CASPubMedWeb of Science®Google Scholar 101Inoue Y, Miyamura T, Unayama T, et al. Maternal transfer of HCV. Nature 1991; 353: 609 10.1038/353609a0 CASPubMedWeb of Science®Google Scholar 102Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330: 774–50. 10.1056/NEJM199403173301103 Web of Science®Google Scholar 103Nowicki MJ, Balistreri WF. The hepatitis C virus: identification, epidemiology and clinical controversies. J Pediatr Gastroenterol Nutr 1995; 20: 248–74. 10.1002/j.1536-4801.1995.tb11551.x CASPubMedWeb of Science®Google Scholar 104Ruiz-Moreno M, Rua MJ, Castillo I, et al. Treatment of children with chronic hepatitis C with recombinant interferon-alfa: a pilot study. Hepatology 1992; 16: 882–5. 10.1002/hep.1840160405 CASPubMedWeb of Science®Google Scholar 105Iono R, Farriello I, Guida S, et al. Alpha lymphobiastoid interferon therapy in 12 children with chronic hepatitis C [Abstract]. Hepatology 1993; 18: A237 Google Scholar 106Gowans EJ, Bonino F. Hepatitis delta virus pathogenicity. Prog Clin Biol Res 1993; 382: 125–30. CASPubMedGoogle Scholar 107Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88–94. 10.1056/NEJM199401133300202 CASPubMedWeb of Science®Google Scholar 108Hadziyannis SJ. Use of alpha-interferon in the treatment of chronic delta hepatitis. J Hepatol 1991; 13(suppl): 21–6. 10.1016/0168-8278(91)91716-T PubMedGoogle Scholar 109Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatmeht of chronic hepatitis D virus infection with low and high doses of interferon alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994; 19: 1331–6. 10.1002/hep.1840190602 CASPubMedWeb of Science®Google Scholar 110Kleiner D, DiBisceglie AM, Axiotis CA, Hoofnagle JH. Prolonged alpha interferon therapy for chronic delta hepatitis: effect on liver histopathology. Prog Clin Biol Res 1993; 382: 365–71. CASPubMedGoogle Scholar 111Kay MH, Wyllie R, Deimler C, et al. Alpha interferon therapy in children with chronic active hepatitis B and delta virus infection. J Pediatr 1993; 123: 1001–4. 10.1016/S0022-3476(05)80402-0 CASPubMedWeb of Science®Google Scholar 112Craxi A, DiMarco V, Volpes R, et al. Treatment with recombinant alpha2b-interferon of chronic HDV hepatitis in children. Prog Clin Biol Res 1991; 364: 399–404. CASPubMedWeb of Science®Google Scholar 113Perillo RP, Regenstein FG, Roodman St. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986; 105: 382–3. 10.7326/0003-4819-105-3-382 PubMedWeb of Science®Google Scholar 114McDonald JA, Karayiannis P, Scully LJ, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HIV-III antibodies to recombinant alfa interferon. Hepatology 1987; 7: 719–23. 10.1002/hep.1840070417 CASPubMedWeb of Science®Google Scholar 115Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994; 20: 1152–5. 10.1002/hep.1840200508 CASPubMedWeb of Science®Google Scholar 116Boyer N, Marcelin P, Degott C, et al. Recombinant interferon alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992; 165: 723–6. 10.1093/infdis/165.4.723 CASPubMedWeb of Science®Google Scholar 117Vento S, DiPerri G, Cruciani M, et al. Rapid decline in CD4+ cells after IFN alfa treatment in HIV-I infection. Lancet 1993; 341: 958–9. 10.1016/0140-6736(93)91248-K CASPubMedWeb of Science®Google Scholar 118Chan TM, Lok AS, Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. Transplantation 1993; 56: 1095–8. 10.1097/00007890-199311000-00009 CASPubMedWeb of Science®Google Scholar 119Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20: 24–7S. 10.1002/hep.1840200708 PubMedWeb of Science®Google Scholar 120Hopf U, Neuhaus P, Lobeck H, et al. Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha. J Hepatol 1991; 13: 339–46. 10.1016/0168-8278(91)90078-P CASPubMedWeb of Science®Google Scholar 121VanThiel DH, Wright HI, Gavaler JS, Fung J, Starzl TE. Interferon therapy of hepatitis following liver transplantation under FK506 or cyclosporine. Transplant Proc 1991; 23: 3052–3. CASPubMedWeb of Science®Google Scholar 122Hirsch MS, Schooley RT, Cosimi AB, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med 1983; 308: 1489–93. 10.1056/NEJM198306233082501 CASPubMedWeb of Science®Google Scholar 123Sonnenblick M, Rosin A. Cardiotoxicity and interferon. A review of 44 cases. Chest 1991; 99: 557–61. 10.1378/chest.99.3.557 CASPubMedWeb of Science®Google Scholar 124Mattson K, Niiranen A, Iiavanainen M, et al. Neurotoxicity of interferon. Cancer Treat Rep 1983; 67: 958–61. CASPubMedWeb of Science®Google Scholar 125Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350–6. 10.1001/archopht.1993.01090030068041 CASPubMedWeb of Science®Google Scholar 126Kassanides C, DiBisceglie AM, Hoofnagle JH, et al. Alpha interferon therapy in patients with decompensated chronic type B hepatitis. In: AJ Zuckerman, eds. Viral hepatitis and liver diseases. New York: Liss, 1988: 840–3. Google Scholar 127Fattovich G, Betterle C, Brollo L, et al. Autoantibodies during alfa interferon therapy for chronic hepatitis B. Br J Med Virol 1991; 34: 132–5. 10.1002/jmv.1890340212 CASPubMedWeb of Science®Google Scholar 128Black M, Petrus M. Alpha-interferon treatment of chronic hepatitis C: need for accurate diagnosis in selecting patients. Ann Intern Med 1992; 116: 86–8. 10.7326/0003-4819-116-1-86 CASPubMedWeb of Science®Google Scholar 129Silva MO, Reddy KJ, Jeffers LJ, et al. Interferon induced chronic active hepatitis. Gastroenterology 1991; 101: 840–2. 10.1016/0016-5085(91)90547-X CASPubMedWeb of Science®Google Scholar 130Shindo M, DiBisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102: 1406–8. 10.1016/0016-5085(92)90786-X CASPubMedWeb of Science®Google Scholar 131Ruiz-Moreno M, Rua MJ, Carreno V, et al. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol 1991; 12: 265–6. 10.1016/0168-8278(91)90953-9 CASPubMedWeb of Science®Google Scholar 132Lisker-Melman M, DiBisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155–60. 10.1016/0016-5085(92)90348-3 CASPubMedWeb of Science®Google Scholar 133Marcellin P, Ponteau M, Renard P, et al. Sustained hypothyroidism induced by recombinant alfa interferon in patients with chronic hepatitis C. Gut 1992; 33: 855–6. 10.1136/gut.33.6.855 CASPubMedWeb of Science®Google Scholar 134Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90: 363–7. 10.1111/j.1365-2249.1992.tb05852.x CASPubMedWeb of Science®Google Scholar 135Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon alfa therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89: 399–403. CASPubMedWeb of Science®Google Scholar 136Lopez-Morante AJ, Saez-Royuela F, Casanova-Valero F, et al. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C. Am J Gastroenterol 1992; 87: 809–10. CASPubMedWeb of Science®Google Scholar 137Chazerain P, Meyer O, Kahn MF. Rheumatoid arthritis-like disease after alpha-interferon therapy. Ann Intern Med 1992; 116: 427 10.7326/0003-4819-116-5-427_1 CASPubMedWeb of Science®Google Scholar 138Fabris P, Betterle C, Florean A, et al. Development of type I diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis [Letter]. Lancet 1992; 340: 548 10.1016/0140-6736(92)91744-S CASPubMedWeb of Science®Google Scholar 139Koivisto VA. Interferon alfa and development of type I diabetes mellitus. Lancet 1992; 340: 1236 10.1016/0140-6736(92)92944-B CASPubMedWeb of Science®Google Scholar 140Funk J, Langeland T, Schrumpf E, et al. Psoriasis induced by interferon alpha. Br J Dermatol 1991; 125: 463–5. 10.1111/j.1365-2133.1991.tb14774.x CASPubMedWeb of Science®Google Scholar 141Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermuller K-H. Exacerbation of lichen planus during interferon alfa 2b therapy for chronic active hepatitis C. Gastroenterology 1993; 104: 903–5. 10.1016/0016-5085(93)91029-H CASPubMedWeb of Science®Google Scholar 142Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987; 147: 1577–80. 10.1001/archinte.1987.00370090055011 CASPubMedWeb of Science®Google Scholar 143Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liv Dis 1989; 9: 273–7. 10.1055/s-2008-1040523 CASPubMedWeb of Science®Google Scholar 144Janssen HL, Berk L, Vermeulen M, et al. Seizures associated with low dose of alpha interferon. Lancet 1990; 336: 22–9. 10.1016/0140-6736(90)93356-T Web of Science®Google Scholar 145Miller VS, Zweiner RJ, Fielman BA. Interferon-associated refractory status epilepticus. Pediatrics 1994; 93: 511–2. 10.1542/peds.93.3.511 CASPubMedWeb of Science®Google Scholar 146Graessie D, Bonacini M, Chen S. Alpha-interferon and reversible hypertriglyceridemia. Ann Intern Med 1993; 118: 316–7. 10.7326/0003-4819-118-4-199302150-00026 Web of Science®Google Scholar 147Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75. 10.7326/0003-4819-122-9-199505010-00004 CASPubMedWeb of Science®Google Scholar 148Louis-Jacques O, Olson AD. Cost-effectiveness analysis of interferon alpha 2B therapy in children with chronic active hepatitis B. [Abstract]. Gastroenterology 1995; 108: A1114 10.1016/0016-5085(95)28756-6 Google Scholar 149Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994; 160: 268–72. 10.5694/j.1326-5377.1994.tb125830.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume23, Issue2August 1996Pages 93-106 ReferencesRelatedInformation